A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
about
T-cell lymphomas, a challenging disease: types, treatments, and future.A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.Therapeutic Options for Aggressive T-Cell Lymphomas.The discovery and development of romidepsin for the treatment of T-cell lymphoma.How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future.Treatment approaches of hard-to-treat non-Hodgkin lymphomas.A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.Recent advances in understanding and managing T-cell lymphoma.A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma.Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells.Peripheral T-cell lymphomas: very little good, mainly the bad and the ugly.Dihydroartemisinin triggers c-Myc proteolysis and inhibits protein kinase B/glycogen synthase kinase 3β pathway in T-cell lymphoma cellsCurrent Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas
P2860
Q30244553-7657E9B7-AEC7-43A9-A64A-8E0206F2A765Q33431457-650E090E-3524-43DA-9186-70F92CA843A8Q38675843-4EA52421-2213-40B7-8530-04F4BBA405CBQ38713744-0816BB43-5D29-46EA-966D-61D80F168E60Q38782072-AAE3F7DE-6FE4-4A25-BB0F-7D6953FA0EA5Q39091822-094B3CEB-C973-4B87-B727-C0926FD32C1DQ40444551-0E1DBC06-8B33-4D51-9F01-8589962F9A1DQ47131247-298B6E9E-2408-4B9B-8778-FA0751E519C4Q48297516-2FD7FA05-F203-472A-AAD7-5EBEB4461517Q48567161-7A74BAD5-7CD1-453F-8145-2388D294F91FQ49290997-96C58024-BA7A-4423-9A54-157087D8B199Q52767296-40F7CFAA-4892-4A54-AF23-52E2D8AFABC1Q58571993-770EC2A2-A122-4E28-AFC3-3FC67F5E3BA6Q58723337-80CC9BAD-DC29-4BE3-B7F8-13BE26334AA5
P2860
A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
description
2015 nî lūn-bûn
@nan
2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
A phase II study of cyclophosp ...... the T- cell consortium trial.
@ast
A phase II study of cyclophosp ...... the T- cell consortium trial.
@en
type
label
A phase II study of cyclophosp ...... the T- cell consortium trial.
@ast
A phase II study of cyclophosp ...... the T- cell consortium trial.
@en
prefLabel
A phase II study of cyclophosp ...... the T- cell consortium trial.
@ast
A phase II study of cyclophosp ...... the T- cell consortium trial.
@en
P2093
P2860
P50
P356
P1476
A phase II study of cyclophosp ...... the T- cell consortium trial.
@en
P2093
Andrei R Shustov
Anne W Beaven
Fausto Loberiza
Francine Foss
Kenneth R Carson
Kerry J Savage
Lauren C Pinter-Brown
Mary J Lechowicz
Ranjana H Advani
Sonali M Smith
P2860
P304
P356
10.1111/BJH.13855
P407
P577
2015-12-02T00:00:00Z